Scientific program

Thursday, October 26, 2017

 14:00 – 14:15 Congress Opening Hall 1
 14:15 – 15:30 Plenary Session 1:
Breast cancer genetics		 Hall 1
Chairpersons Hideko Yamauchi, Japan
Alastair Thompson, USA
 14:15 – 14:45
14:15
14:30		 Debate: That liberal use of genetic testing should be encouraged
Yes: Arlene Chan, Australia
No: Nick Wilcken, Australia
 14:45 – 15:05 Management of genetic mutation carriers
Ava Kwong, Hong Kong
 15:05 – 15:30 Panel discussion: Controversial cases
Arlene Chan, Australia
Nick Wilcken, Australia
Ava Kwong, Hong Kong
15:30 – 17:00 Plenary Session 2:
Neoadjuvant therapy		 Hall 1
Chairpersons Hiroji Iwata, Japan
Hitoshi Tsuda, Japan
Wolfgang Janni, Germany
15:30 – 16:05
15:30
15:42
15:54		 Debate: That NAST choice should be based on more TN stage rather than on biological subtype
TN Stage: Louis Chow, Hong Kong
Biological subtype: Stacy Moulder, USA
Discussion
16:05 – 16:40
16:05
16:17
16:29		 Debate: That all patients with positive nodes pre-neoadjuvant therapy should have axillary dissection as part of cancer surgery
Yes:  Ian Campbell, New Zealand
No: Abigail Caudle, USA
Discussion
16:40 – 17:00 The role of oral 5FU in the adjuvant setting after primary systemic therapy
Masakazu Toi, Japan
17:30 – 19:00 Industry Symposium:The 21 Gene Assay: The Evidence in 2017
Supported by Genomic Health
 Hall 1

Friday, October 27, 2017

08:00 – 09:00 Morning Industry Symposium: Comprehensive genomic sequencing for breast cancer patients in Japan
Supported by Denka-KEW Genomics
Breakfast will be served prior to the session		 Hall 1
09:00 – 10:00 Plenary Session 3:
Immunotherapy/TNBC		 Hall 1
Chairpersons Shigeru Imoto, Japan
Arlene Chan, Australia
 09:00 – 09:30 PARP inhibitors: Where do they fit in breast cancer management?
Wolfgang Janni, Germany
09:30 – 10:00 Is immunotherapy likely to be a game-changer in breast cancer?
Stephen Chia, Canada
10:00 – 11:00 Plenary Session 4:
Adjuvant endocrine therapy		 Hall 1
Chairpersons Sadako Akashi-Tanaka, Japan
Javier Cortes, Spain
10:00 – 10:30
10:00
10:15		 Debate: That OFS + AI should be standard of care in young patients with high-risk HR+ve breast cancer
Yes: Wolfgang Janni, Germany
No: Richard de Boer, Australia
10:30 – 11:00 Duration of/choice of adjuvant endocrine therapy
Nick Wilcken, Australia
11:30 – 12:30 Parallel Session 5:
Imaging		 Hall 1
Chairpersons Chiun-Sheng Huang, Taiwan
Bruce Mann, Australia
11:30 – 11:50 Breast ultrasound in cancer screening: The J-start experience
Akihiko Suzuki, Japan
11:50 – 12:10 Screening technologies: One size does not fit all
Elizabeth Morris, USA
12:10 – 12:30 What is the best way to assess response to neoadjuvant therapy?
Naoki Hayashi, Japan
11:30 – 12:30 Parallel Session 6:
Her2+ve		 Hall 2
Chairpersons Hiromitsu Jinno, Japan
Stacy Moulder, USA
11:30 – 12:00
11:30
11:40
11:50		 Debate: That neratinib should be offered as a standard of care in adjuvant therapy of Her2+ve breast cancer
Yes: Arlene Chan, Australia
No: Stephen Chia, Canada
Discussion
12:00 – 12:30 State of the art in metastatic Her2+ early breast cancer
Javier Cortes, Spain
12:45 – 13:45 Luncheon Industry Symposium: The tumor microenvironment in breast cancer progression:  Clinical implications for OS benefit
Supported by Eisai 
 Hall 1
12:45 – 13:45 Luncheon Industry Symposium: Current situation and future perspective of HBOC practice in Japan
Supported by AstraZeneca		 Hall 2
14:00 – 15:30 Plenary Session 7:
Locoregional therapy		 Hall 1
Chairpersons Won Shik Han, Korea
Shinobu Masuda, Japan
Ian Campbell, New Zealand
14:00 – 14:20 What is the optimal way to achieve clear margins in BCS?
Alastair Thompson, USA
14:20 – 14:55
14:20
14:32
14:44		 Debate: That regional nodal radiotherapy is required in all early stage node positive breast cancer
Yes: Sanjoy Chatterjee, India
No: Louis Chow, Hong Kong
Discussion
14:55 – 15:30
14:55
15:07
15:19		 Debate: That surgical axillary assessment should be routine for all patients with invasive breast cancer
Yes: Koichiro Tsugawa, Japan
 No: Abigail Caudle, USA
Discussion
 15:30 – 16:30 Parallel Session 8:
DCIS		 Hall 1
Chairpersons Jin Zhang, China
Abigail Caudle, USA
15:30 – 15:50 Biology of DCIS
Sunil R. Lakhani, Australia
15:50 – 16:30
15:50
16:05
16:20		 Debate: That active surveillance for low risk DCIS should be considered
Yes: Alastair Thompson, USA
 No: Raghu Ram, India
Discussion
15:30 – 16:30 Parallel Session 9:
Free Papers		 Hall 2
Chairpersons Javier Cortes, Spain
Hidetaka Kawabata, Japan
15:30-15:40 Comparison of prognostic performance of oncotype DX recurrence score versus EndoPredict (EPclin) in women with intermediate risk of recurrence by Nottingham Prognostic Index
Ivana Sestak, UK
15:40-15:50 The role of antibiotics in breast pocket irrigation and implant immersion during breast surgery: A systematic review and meta-analysis
Ashley Frois, Australia
Patrick Harbour, Australia
15:50-16:00 Targeting cancer metabolism enhances the effect of anti-cancer drug in breast cancer cells
Sung-Eun Hong, Korea
16:00-16:10 Rate and significance of extra-capsular extension in breast cancer positive sentinel lymph nodes
Oded Olsha, Israel
16:10-16:20 Hypo-fractionated radiotherapy (RT) schedule of 35Gy in 10 fractions in advanced incurable breast cancer: A prospective phase I/II study
Mandira Saha, India
16:20-16:30 Patient reported outcomes according to receipt of neoadjuvant or adjuvant systemic therapy for breast cancer: Results of a prospective longitudinal study
Nicholas Zdenkowski, Australia
17:00 – 18:30 Industry Symposium: New treatment strategy for HR-positive and HER2 negative metastatic breast cancer patients
Supported by Pfizer		 Hall 1

Saturday, October 28, 2017

08:30 – 09:30 Morning Special Lecture: Controversies on breast cancer screening: Adjunctive ultrasonography for women with dense breast (J-START)
 Hall 1
Chairperson Takayoshi Uematsu, Japan
Speaker Noriaki Ohuchi, Japan
08:30 – 09:30 Morning Industry Symposium: Treatment strategy for HER2-positive metastatic breast cancer
Supported by Chugai
Breakfast will be served prior to the session		 Hall 2
09:45 – 10:45 Parallel Session 10:
Reconstruction/radiation		 Hall 1
Chairpersons Yasuhiro Ogawa, Japan
Alastair Thompson, USA
09:45 – 10:15
09:45
09:55
10:05		 Debate: That chest wall radiotherapy prior to mastectomy and reconstruction is a good option
Yes: Sanjoy Chatterjee, India
No: Ian Campbell, New Zealand
Discussion
10:15 – 10:45
10:15
10:30		 Debate: That fear and ignorance drive the rise in contralateral prophylactic mastectomy
Yes: Hideko Yamauchi, Japan
 No: Bruce Mann, Australia
09:45 – 10:45 Parallel Session 11:
Free Papers		 Hall 2
Chairpersons Richard de Boer, Australia
Hiroko Bando, Japan
09:45-09:55 Is nipple-sparing mastectomy with immediate reconstruction safe for Asian women? An 11-year review
Yvonne Ng, Singapore
09:55-10:05 Clinical utility of adding 21-Gene Recurrence Score to standard treatment decisions in early-stage hormone receptor-positive breast cancer
Yasue Tsuchida, Japan
10:05-10:15 Surveillance of the reconstructed breast following breast surgery: To image or not to image?
Su Ang, Australia
10:15-10:25 Can contrast enhanced spectral mammography replace Magnetic Resonance Imaging in the detection and staging of breast lesions?
Mohamed Attia, Egypt
10:25-10:35 How realistic are published breast cancer overdiagnosis rates?
Carolyn Nickson, Australia
10:35-10:45 Improved breast cancer mortality in breast screened patients in New Zealand
Cameron Douglas, Australia
11:15 – 12:45 Plenary Session 12:
Breast cancer 2022		 Hall 1
Chairpersons Bruce Mann, Australia
Seigo Nakamura, Japan
How will breast cancer management change by 2022 for the:
11:15-11:30 Pathologist
Sunil R. Lakhani, Australia
11:30-11:45 Radiologist
Elizabeth Morris, USA
11:45-12:00 Surgeon
Seigo Nakamura, Japan
12:00-12:15 Medical oncologist
Stacy Moulder, USA
12:15-12:30 Radiation oncologist
Sanjoy Chatterjee, India
12:30-12:45 Discussion
12:45 – 13:00 Congress wrap-up and award presentation Hall 1
Chairpersons Bruce Mann, Australia
Seigo Nakamura, Japan
13:15 – 14:15 Luncheon Industry Symposium: Future perspective of oral-FU drug in the management of breast cancer
Supported by Taiho
Hall 1
13:15 – 14:15 Luncheon Industry Symposium: What needs to perform chemotherapy for breast cancer in the current era?
Supported by Kyowa Kirin		 Hall 2
14:30 – 18:25 Young doctors’ summit in Asia Hall 1
Chairpersons Sadako Akashi-Tanaka, Japan
Takahiro Nakayama, Japan
14:30 – 15:10 Debate 1: Management of ductal carcinoma in situ: Is surgical resection needed or not?
Chairpersons Takashi Kuwayama, Japan
Kazuhiko Sato, Japan
Participants Yoko Takahashi, Japan
Miki Hasegawa, Japan
Sho Shiino, Japan
Keiichi Kinowaki, Japan
Joo Heung Kim, Korea
Mohamed Attia, Egypt
Yomna Galaa Sabry Abdelaziz, Egypt
15:15 – 15:55 Debate 2: Imaging modality for dense breast. Which is more effective: ultrasonography or tomosynthesis?
Chairpersons Naoko Matsuda, Japan
Kazunori Kubota, Japan
 Participants Miwa Yoshida, Japan
Yasuyuki Kojima, Japan
Yuki Matsunaga, Japan
Sang-Eun Nam, Korea
Lei Liu, China
Dapeng Lu, China
16:15 – 16:55 Debate 3: Position of gene testing; BRCA mutation test should be used as companion
 Chairpersons Yoshimi Ide, Japan
Reiko Yoshida, Japan
 Participants Yuko Tanabe, Japan
Takamichi Yokoe, Japan
Cheng-Ping Yu, Taiwan
Euitae Kim, Korea
Yan Liu, China
Vivian Man, Hong Kong
Jai Min Ryu, Korea
17:00 – 17:40 Debate 4: Predictive marker for hormone-receptor positive HER2 negative patients; Which do you use for your patients in the clinical management in selecting adjuvant therapy, multigene tests or IHC4?
 Chairpersons Jeong Eon Lee, Korea
Nobuko Tamura, Japan
 Participants Chiaki Nakauchi, Japan
Sakiko Tazawa, Japan
Masahiro Takada, Japan
Yuan-Ching Chang, Taiwan
Young Wook Ju, Korea
Weiliang Feng, China
Yvonne Ng, Singapore
17:45 – 18:25 Debate 5: Treatment of hormone-refractory metastatic breast cancer; Which is more effective:  CDK4/6 inhibitor or mTOR inhibitor?
 Chairpersons Makiko Ono-Fuchiwaki, Japan
Akihiko Shimomura, Japan
 Participants Jun Hashimoto, Japan
Nami Yamashita, Japan
Madoka Iwase, Japan
Hee Jun Choi, Korea
Xiuyan Yu, China